Search 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, life-science company focused on enabling the creation of advanced therapies and biopharmaceuticals utilizing our high quality recombinant human albumin products and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago.

Our vision is to empower excellence in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. As an example, we are proud to be working with domestic, national and international life science companies in these challenging times towards the urgent response against covid-19 - be it diagnostically, therapeutically and prophylactically.

Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex Pharma and Biotech), with a track record in delivering successful clinical stage programmes. Almac Discovery utilises its capabilities and expertise to discover and develop novel first-in-class/best-in-class NCEs and Novel Protein Therapeutics through to IND-ready stage, after which it seeks to collaborate with partners to continue into clinical development.

Its core expertise and arising portfolio are focussed on two areas:
a) Targeting the Deubiquitinating enzyme class (DUBs) linked to protein homeostasis and degradation through the application of its proprietary Ubi-Plex technology platform, and,
b) Next Generation Protein:Drug Conjugate (PDC) technology platform utilising minimal antigen-binding domains combined with Almac's novel, proprietary linker and payload technology.   
Drug programmes derived from these platforms are currently being prosecuted both in house and with external collaborators.

Founded in Oxford in 2016, Arctoris is the world’s first fully automated drug discovery platform.

A global team of biotech and pharma veterans and leading engineers developed and operate Ulysses, our proprietary technology platform. Combining robotics, AI and blockchain, Arctoris is the next step in drug discovery evolution.

Arctoris is trusted by biotech and AI-driven drug discovery companies, pharmaceutical corporations and academic centers on three continents to bring new drugs from idea to IND faster.

Aspire Pharma is an innovative, privately owned British pharmaceutical company established in 2009. We develop medicines that make a difference. Our innovative products are difficult to emulate and are the result of teamwork and creative thought.